Radiosynovectomy's clinical applications and cost effectiveness: A review

https://doi.org/10.1016/S0001-2998(97)80009-8Get rights and content

It is apparent that from the work of the authors and many others, including the work of Rivard, Sledge, Zuckerman, among others, that radiosynovectomy has an important role to play in providing effective treatment of affected joints associated with rheumatoid arthritis and other forms of arthritis as well as the hemophiliac joint. The treatment offers relief from the effects of recurrent joint effusion with an approximately 60% to 66% favorable response and from recurrent hemarthrosis in the hemophiliac joint with an approximately 75% to 80% favorable response. The impact of providing radiosynovectomy as an alternative to surgical synovectomy is seen, where postoperative side effects such as joint stiffness are avoided, improved quality of life is repeatedly documented, and the cost savings in health care dollars, particularly evident in the hemophiliac joint in this relatively small population, are potentially enormous. With almost two million people in the United States suffering from rheumatoid arthritis, the potential savings in health care dollars is also enormous. As with any use of in vivo radiopharmaceuticals, the potential for radiation-induced damage exists. However, with a 25 plus year record of use, more optimally configured radiopharmaceuticals, and the addition of maneuvers to minimize potential joint leakage, the risk of radiation induced damage appears to be minimal. It appears as though radiosynovectomy is an effective as well as cost-effective alternative to surgical synovectomy and is becoming the procedure of choice particularly in the hemophiliac patient with recurrent hemarthrosis and synovitis who has failed medical therapy. It is also the procedure of choice in patients for whom surgery is contraindicated because of the presence of clotting factor inhibitors.

References (40)

  • Ogilvie-HarrisDJ et al.

    Arthroscropic synovectomy of the knee for rheumatoid arthritis

    Arthroscopy

    (1991)
  • ZalutskyMR et al.

    Radiation synovectomy with Dy-165-FhMA: Lymph node uptake and radiation dosimetry calculations

    Int J Nucl Med Biol

    (1986)
  • ZuckermanJD et al.

    Treatment of rheumatoid arthritis using radiopharmaceuticals

    Int J Rad Appl Instrum (B)

    (1987)
  • DahmenG

    Possibilities and dangers of chemical synovectomy

    Hippokrates

    (1971)
  • GristinaAG et al.

    Intra-articular thio-tepa compared with depo-medrol and procaine in the treatment of arthritis

    J Bone Joint Surg Am

    (1970)
  • RivardGE et al.

    Synoviorthesis with colloidal P-32 chromic phosphate for hemophilic arthropathy: Clinical follow-up

    Arch Phys Med Rehabil

    (1985)
  • TriantafyllouSJ et al.

    Open and arthroscopic synovectomy in hemophilic arthropathy of the knee

    Clin Orthop

    (1992)
  • FellingerK et al.

    Die Lokale Vehandlung der Reumatischer Erkrankungen

    Wien Inn Med

    (1952)
  • MerchanECR et al.

    Long-term follow-up of haemophiliac arthropathy treated by Au-198 radiation synovectomy

    Int Orthop

    (1993)
  • Fernandez-PalazziF et al.

    Radioactive synovectomy in haemophiliac haemarthrosis. Follow-up of fifty cases

    Scand J Haematol

    (1984)
  • WinstonMA et al.

    Radioisotope synovectomy with P-32 chromic phosphate-kinetic studies

    J Nucl Med

    (1973)
  • OnettiCM et al.

    Synoviorthesis with P-32 colloidal chronic phosphate in rheumatoid arthritis: Clinical histopathological and arthrographic changes

    J Rheumatol

    (1982)
  • RivardGE et al.

    Synoviortheses with colloidal P32 chromic phosphate for the treatment of hemophilic arthropathy

    J Bone Joint Surg Am

    (1994)
  • SledgeCB et al.

    Synovectomy of the rheumatoid knee using intra-articular injection of dysporosium 165-ferric hydroide macroaggregates

    J Bone Joint Surg Am

    (1987)
  • SledgeCB et al.

    Treatment of rheumatoid synovitis of the knee with intra-articular injection of dysprosium 165-ferric hydroide macroaggregates

    Arthritis Rheum

    (1986)
  • SiegelHJ et al.

    P-32 chromic phosphate colloid radiosynovectomy for hemarthrosis and synovitis in hemophilia (abst)

  • AhlbergA

    Radioactive gold in the treatment of chronic synovial effusion in hemophiolia

  • Fernandez-PalazziF et al.

    Radioactive synoviorthesis in hemophiliac Hemarthrosis: Materials, techniques and dangers

    Clin Orthop

    (1996)
  • ErkenEHW

    Radiocolloids in the management of hemophiliac arthropathy in children and adolescents

    Clin Orthop

    (1991)
  • HeimM et al.

    Methods and results of radionucleotide synovectomies

    Ort Traum Oggi

    (1990)
  • Cited by (73)

    • Radiochemical processing of nuclear-reactor-produced radiolanthanides for medical applications

      2019, Coordination Chemistry Reviews
      Citation Excerpt :

      The use of 165Dy (t1/2 = 2.334 h) in modern nuclear medicine is rather scarce, if not abandoned because of better available alternatives (e.g. 169Er). Examples of 165Dy being used in nuclear medicine mainly describe application in radiosynovectomy [121–126]. Joints affected by arthritis can be treated by its β− particle emission of 1.286 MeV, which has a maximum soft tissue range of 5.7 mm and a mean soft tissue range of 1.8 mm.

    • Reactor production and electrochemical purification of <sup>169</sup>Er: A potential step forward for its utilization in in vivo therapeutic applications

      2014, Nuclear Medicine and Biology
      Citation Excerpt :

      Radiation synovectomy (RSV), which involves intraarticular injection of beta-emitting radionuclides in colloidal or particulate form (1–10 μm size range) into the affected synovial joints, has emerged as an effective treatment modality in patients suffering from inflammatory-rheumatoid and degenerative joint diseases [1–7].

    • Options to meet the future global demand of radionuclides for radionuclide therapy

      2013, Nuclear Medicine and Biology
      Citation Excerpt :

      Radiolabeled particulates and microspheres have also found successful applications in treating liver cancer [27–31]. Particulates labeled with radionuclides such as 90Y, 169Er and 32P are being explored for radiosynovectomy, which is a non-cancer application [32–35]. Considering the large interest that is being generated recently in this field, it can be expected that there will be an expanding demand for therapeutic radionuclides in near future.

    • Synopsis of Pathophysiology in Nuclear Medicine, Second Edition

      2023, Synopsis of Pathophysiology in Nuclear Medicine, Second Edition
    View all citing articles on Scopus
    View full text